Who founded KaloCyte?

KaloCyte was founded by Allan Doctor, Dipanjan Pan, Philip Spinella in 2016.

Who are KaloCyte's investors?

KaloCyte's investors include BioAdvance, BioGenerator Ventures, Delaware Crossing Investor Group, Maryland TEDCO, NYBC Ventures, Old Line Capital Partners, TEDCO, University System of Maryland Momentum Fund.

How much funding has KaloCyte raised?

KaloCyte has disclosed $800K raised across 1 round.

Where is KaloCyte headquartered?

KaloCyte is headquartered in Baltimore, US.

KaloCyte

Baltimore, US · Founded 2016 · Missouri corporation · 23 employees on LinkedIn · 8 known investors

Find your way into KaloCyte

Paths you didn't know you had: your email and LinkedIn already hold routes to the KaloCyte team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

KaloCyte was founded in 2016 by Allan Doctor, Dipanjan Pan, and Philip Spinella.

Allan DoctorCo-Founder & CSO

Dipanjan Pan Co-Founder, Chief Technical OfficerDipanjan Pan is Co-Founder and Chief Technical Officer of KaloCyte, a biotech company developing artificial red blood cells for emergency and trauma care. His expertise spans nanomedicine, molecular imaging, drug delivery, polymer chemistry, and nanotechnology.

Philip Spinella Co-Founder, Chief Medical OfficerPhilip Spinella is a professor of surgery and critical care medicine at the University of Pittsburgh who leads a transfusion medicine research program focused on improving outcomes for critically ill patients, with prior service as a lieutenant colonel in the U.S. Army Medical Corps where he deployed to Iraq and contributed to the development of damage control resuscitation protocols.

Daniel GetmanNamed on SEC filing

Gregory LanzaNamed on SEC filing

Investors · 8

BioAdvancelisted by BioAdvanceConshohocken · $500K – $1.5M

How we know: BioAdvance's portfolio page · Not right? Tell us

BioGenerator Ventureslisted by BioGenerator VenturesSt. Louis · $50K – $250K

How we know: BioGenerator Ventures's portfolio page · Not right? Tell us

Delaware Crossing Investor Grouplisted by Delaware Crossing Investor GroupPhiladelphia

How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us

Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M

How we know: Maryland TEDCO's portfolio page · Not right? Tell us

NYBC Ventureslisted by NYBC VenturesNew York

Old Line Capital Partnerslisted by Old Line Capital PartnersBowie

TEDCOlisted by TEDCOColumbia

University System of Maryland Momentum Fundlisted by University System of Maryland Momentum FundBaltimore · $150K – $500K

How we know: University System of Maryland Momentum Fund's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$800K disclosed across 1 round · 2018

▶$800KraisedMay 2018 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Dipanjan PanDirector
Daniel GetmanDirector
Allan DoctorExecutive Officer, Director
Gregory LanzaDirector
Philip SpinellaDirector

Offering amount: $800K
Amount sold: $800K
Minimum investment: $10K
First sale: Apr 2018
Incorporated: Corporation, Missouri, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

University of British ColumbiaThe University of British Columbia is a public university offering academic programs, research, and campus events across areas such as environmental science, business, music, and agriculture. It serves students, faculty, staff, and the public in British Columbia, Canada.

Companies working in the same space as KaloCyte.

Frequently asked questions

What does KaloCyte do?: KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.
Who founded KaloCyte?: KaloCyte was founded by Allan Doctor, Dipanjan Pan, Philip Spinella in 2016.
Who are KaloCyte's investors?: KaloCyte's investors include BioAdvance, BioGenerator Ventures, Delaware Crossing Investor Group, Maryland TEDCO, NYBC Ventures, Old Line Capital Partners, TEDCO, University System of Maryland Momentum Fund.
How much funding has KaloCyte raised?: KaloCyte has disclosed $800K raised across 1 round.
Where is KaloCyte headquartered?: KaloCyte is headquartered in Baltimore, US.